Cargando…

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation

Detalles Bibliográficos
Autores principales:	Janardan, Sanyukta, Horwitz, Edwin, Watkins, Benjamin, Williams, Kirsten, Chandrakasan, Shanmuganathan, Qayed, Muna, Parikh, Suhag, Arnold, Staci, Keller, Frank, Alazraki, Adina, Schoettler, Michelle, Leung, Kathryn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131924/ https://www.ncbi.nlm.nih.gov/pubmed/35078207 http://dx.doi.org/10.1182/bloodadvances.2021006535

Ejemplares similares

Favorable Outcomes of Pediatric Hematopoietic Cell Transplant Patients Receiving Regen-COV2 for Prophylaxis Against Severe COVID-19 Disease
por: Graham, Rudi-Ann Tamara, et al.
Publicado: (2022)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children
por: Schoettler, Michelle, et al.
Publicado: (2022)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality
por: Schoettler, Michelle L., et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
por: Chandrakasan, Shanmuganathan, et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art
por: Connelly, James A, et al.
Publicado: (2018)

236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant
por: Liberio, Nicole, et al.
Publicado: (2022)

2136: Gut microbiome alterations in children undergoing hematopoietic stem cell transplantation
por: Qayed, Muna, et al.
Publicado: (2018)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Editorial: Dermatologic manifestations of primary immune deficiency disorders in children
por: Shamriz, Oded, et al.
Publicado: (2023)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT
por: Kissane, E., et al.
Publicado: (2022)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

Editorial: NK cell defects: diagnosis and treatment
por: Shabrish, Snehal, et al.
Publicado: (2023)

41. Impact of Gut Microbiome Changes on Hematopoietic Stem Cell Transplantation Outcomes in Children
por: Teherani, Mehgan, et al.
Publicado: (2020)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund, Audrey M, et al.
Publicado: (2020)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4evp598fhfg2a0ji4414mvh0g